Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism
The anxiolytic effects of aniracetam have not been proven in animals despite its clinical usefulness for post-stroke anxiety. This study, therefore, aimed to characterize the anxiolytic effects of aniracetam in different anxiety models using mice and to examine the mode of action. In a social intera...
Gespeichert in:
| Veröffentlicht in: | European journal of pharmacology 2001-05, Vol.420 (1), p.33-43 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 43 |
|---|---|
| container_issue | 1 |
| container_start_page | 33 |
| container_title | European journal of pharmacology |
| container_volume | 420 |
| creator | Nakamura, Kazuo Kurasawa, Mitsue |
| description | The anxiolytic effects of aniracetam have not been proven in animals despite its clinical usefulness for post-stroke anxiety. This study, therefore, aimed to characterize the anxiolytic effects of aniracetam in different anxiety models using mice and to examine the mode of action. In a social interaction test in which all classes (serotonergic, cholinergic and dopaminergic) of compounds were effective, aniracetam (10–100 mg/kg) increased total social interaction scores (time and frequency), and the increase in the total social interaction time mainly reflected an increase in trunk sniffing and following. The anxiolytic effects were completely blocked by haloperidol and nearly completely by mecamylamine or ketanserin, suggesting an involvement of nicotinic acetylcholine, 5-HT
2A and dopamine D
2 receptors in the anxiolytic mechanism. Aniracetam also showed anti-anxiety effects in two other anxiety models (elevated plus-maze and conditioned fear stress tests), whereas diazepam as a positive control was anxiolytic only in the elevated plus-maze and social interaction tests. The anxiolytic effects of aniracetam in each model were mimicked by different metabolites (i.e.,
p-anisic acid in the elevated plus-maze test) or specific combinations of metabolites. These results indicate that aniracetam possesses a wide range of anxiolytic properties, which may be mediated by an interaction between cholinergic, dopaminergic and serotonergic systems. Thus, our findings suggest the potential usefulness of aniracetam against various types of anxiety-related disorders and social failure/impairments. |
| doi_str_mv | 10.1016/S0014-2999(01)01005-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70942342</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299901010056</els_id><sourcerecordid>70942342</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-1ff7cb9ed2b688476f5e1be5621433c4c9d16548bd3eb2d1622baf49d459593e3</originalsourceid><addsrcrecordid>eNqFkVFLHDEQgEOp1PPsT2gJFKR9WM1kk93NUxGpVRB80D6HbDLppexmbbJXvH9v9Bb7KISZwHwzGb4Q8gnYKTBozu4YA1FxpdRXBt8YMCar5h1ZQdeqirXA35PVK3JIjnL-wwqjuPxADgEE8K5uV2RzHh_DNOzmYCl6j3bOdPLUxJCMxdmMNEQ6bxIidaHUE8aZjtM2Y4kOh4V-DDjvSnaFRbqNDtOwC_E3HdFuyrA8HpMDb4aMH5e8Jr8uf9xfXFU3tz-vL85vKiuknCvwvrW9Qsf7putE23iJ0KNsOIi6tsIqB40UXe9q7Hm5c94bL5QTUklVY70mJ_u5D2n6u8U86zFki8NgIpa1dcuU4HU5ayL3oE1Tzgm9fkhhNGmngelnxfpFsX72pxnoF8W6KX2flwe2_Yjuf9fitABfFsBkawafTLQhv3JKdQq6Qn3fU8Uh_guYdLYBo0UXUvkF7abwxiJPQWKZCw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70942342</pqid></control><display><type>article</type><title>Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Nakamura, Kazuo ; Kurasawa, Mitsue</creator><creatorcontrib>Nakamura, Kazuo ; Kurasawa, Mitsue</creatorcontrib><description>The anxiolytic effects of aniracetam have not been proven in animals despite its clinical usefulness for post-stroke anxiety. This study, therefore, aimed to characterize the anxiolytic effects of aniracetam in different anxiety models using mice and to examine the mode of action. In a social interaction test in which all classes (serotonergic, cholinergic and dopaminergic) of compounds were effective, aniracetam (10–100 mg/kg) increased total social interaction scores (time and frequency), and the increase in the total social interaction time mainly reflected an increase in trunk sniffing and following. The anxiolytic effects were completely blocked by haloperidol and nearly completely by mecamylamine or ketanserin, suggesting an involvement of nicotinic acetylcholine, 5-HT
2A and dopamine D
2 receptors in the anxiolytic mechanism. Aniracetam also showed anti-anxiety effects in two other anxiety models (elevated plus-maze and conditioned fear stress tests), whereas diazepam as a positive control was anxiolytic only in the elevated plus-maze and social interaction tests. The anxiolytic effects of aniracetam in each model were mimicked by different metabolites (i.e.,
p-anisic acid in the elevated plus-maze test) or specific combinations of metabolites. These results indicate that aniracetam possesses a wide range of anxiolytic properties, which may be mediated by an interaction between cholinergic, dopaminergic and serotonergic systems. Thus, our findings suggest the potential usefulness of aniracetam against various types of anxiety-related disorders and social failure/impairments.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/S0014-2999(01)01005-6</identifier><identifier>PMID: 11412837</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>8-Hydroxy-2-(di-n-propylamino)tetralin - pharmacology ; Animals ; Aniracetam ; Anti-Anxiety Agents - pharmacology ; Anxiety ; Anxiety - physiopathology ; Anxiety - prevention & control ; Anxiety - psychology ; Behavior, Animal - drug effects ; Biological and medical sciences ; Bromocriptine - pharmacology ; Conditioned fear stress ; Diazepam - pharmacology ; Disease Models, Animal ; Dopamine Antagonists - pharmacology ; Dose-Response Relationship, Drug ; Elevated plus-maze ; Fear - psychology ; Fluvoxamine - pharmacology ; Haloperidol - pharmacology ; Indophenol - analogs & derivatives ; Indophenol - pharmacology ; Male ; Maze Learning - drug effects ; Mecamylamine - pharmacology ; Medical sciences ; Mice ; Mice, Inbred ICR ; Moclobemide - pharmacology ; Mode of action ; Motor Activity - drug effects ; Neuropharmacology ; Nicotine - pharmacology ; Nicotinic Antagonists - pharmacology ; Nortriptyline - pharmacology ; Pharmacology. Drug treatments ; Physostigmine - pharmacology ; Picolinic Acids - pharmacology ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Pyrrolidinones - pharmacology ; Serotonin Antagonists - pharmacology ; Serotonin Receptor Agonists - pharmacology ; Social Behavior ; Social interaction ; Stress, Psychological - physiopathology ; Stress, Psychological - prevention & control ; Stress, Psychological - psychology</subject><ispartof>European journal of pharmacology, 2001-05, Vol.420 (1), p.33-43</ispartof><rights>2001 Elsevier Science B.V.</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-1ff7cb9ed2b688476f5e1be5621433c4c9d16548bd3eb2d1622baf49d459593e3</citedby><cites>FETCH-LOGICAL-c455t-1ff7cb9ed2b688476f5e1be5621433c4c9d16548bd3eb2d1622baf49d459593e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0014-2999(01)01005-6$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=998918$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11412837$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakamura, Kazuo</creatorcontrib><creatorcontrib>Kurasawa, Mitsue</creatorcontrib><title>Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>The anxiolytic effects of aniracetam have not been proven in animals despite its clinical usefulness for post-stroke anxiety. This study, therefore, aimed to characterize the anxiolytic effects of aniracetam in different anxiety models using mice and to examine the mode of action. In a social interaction test in which all classes (serotonergic, cholinergic and dopaminergic) of compounds were effective, aniracetam (10–100 mg/kg) increased total social interaction scores (time and frequency), and the increase in the total social interaction time mainly reflected an increase in trunk sniffing and following. The anxiolytic effects were completely blocked by haloperidol and nearly completely by mecamylamine or ketanserin, suggesting an involvement of nicotinic acetylcholine, 5-HT
2A and dopamine D
2 receptors in the anxiolytic mechanism. Aniracetam also showed anti-anxiety effects in two other anxiety models (elevated plus-maze and conditioned fear stress tests), whereas diazepam as a positive control was anxiolytic only in the elevated plus-maze and social interaction tests. The anxiolytic effects of aniracetam in each model were mimicked by different metabolites (i.e.,
p-anisic acid in the elevated plus-maze test) or specific combinations of metabolites. These results indicate that aniracetam possesses a wide range of anxiolytic properties, which may be mediated by an interaction between cholinergic, dopaminergic and serotonergic systems. Thus, our findings suggest the potential usefulness of aniracetam against various types of anxiety-related disorders and social failure/impairments.</description><subject>8-Hydroxy-2-(di-n-propylamino)tetralin - pharmacology</subject><subject>Animals</subject><subject>Aniracetam</subject><subject>Anti-Anxiety Agents - pharmacology</subject><subject>Anxiety</subject><subject>Anxiety - physiopathology</subject><subject>Anxiety - prevention & control</subject><subject>Anxiety - psychology</subject><subject>Behavior, Animal - drug effects</subject><subject>Biological and medical sciences</subject><subject>Bromocriptine - pharmacology</subject><subject>Conditioned fear stress</subject><subject>Diazepam - pharmacology</subject><subject>Disease Models, Animal</subject><subject>Dopamine Antagonists - pharmacology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Elevated plus-maze</subject><subject>Fear - psychology</subject><subject>Fluvoxamine - pharmacology</subject><subject>Haloperidol - pharmacology</subject><subject>Indophenol - analogs & derivatives</subject><subject>Indophenol - pharmacology</subject><subject>Male</subject><subject>Maze Learning - drug effects</subject><subject>Mecamylamine - pharmacology</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred ICR</subject><subject>Moclobemide - pharmacology</subject><subject>Mode of action</subject><subject>Motor Activity - drug effects</subject><subject>Neuropharmacology</subject><subject>Nicotine - pharmacology</subject><subject>Nicotinic Antagonists - pharmacology</subject><subject>Nortriptyline - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Physostigmine - pharmacology</subject><subject>Picolinic Acids - pharmacology</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Pyrrolidinones - pharmacology</subject><subject>Serotonin Antagonists - pharmacology</subject><subject>Serotonin Receptor Agonists - pharmacology</subject><subject>Social Behavior</subject><subject>Social interaction</subject><subject>Stress, Psychological - physiopathology</subject><subject>Stress, Psychological - prevention & control</subject><subject>Stress, Psychological - psychology</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkVFLHDEQgEOp1PPsT2gJFKR9WM1kk93NUxGpVRB80D6HbDLppexmbbJXvH9v9Bb7KISZwHwzGb4Q8gnYKTBozu4YA1FxpdRXBt8YMCar5h1ZQdeqirXA35PVK3JIjnL-wwqjuPxADgEE8K5uV2RzHh_DNOzmYCl6j3bOdPLUxJCMxdmMNEQ6bxIidaHUE8aZjtM2Y4kOh4V-DDjvSnaFRbqNDtOwC_E3HdFuyrA8HpMDb4aMH5e8Jr8uf9xfXFU3tz-vL85vKiuknCvwvrW9Qsf7putE23iJ0KNsOIi6tsIqB40UXe9q7Hm5c94bL5QTUklVY70mJ_u5D2n6u8U86zFki8NgIpa1dcuU4HU5ayL3oE1Tzgm9fkhhNGmngelnxfpFsX72pxnoF8W6KX2flwe2_Yjuf9fitABfFsBkawafTLQhv3JKdQq6Qn3fU8Uh_guYdLYBo0UXUvkF7abwxiJPQWKZCw</recordid><startdate>20010518</startdate><enddate>20010518</enddate><creator>Nakamura, Kazuo</creator><creator>Kurasawa, Mitsue</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010518</creationdate><title>Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism</title><author>Nakamura, Kazuo ; Kurasawa, Mitsue</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-1ff7cb9ed2b688476f5e1be5621433c4c9d16548bd3eb2d1622baf49d459593e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>8-Hydroxy-2-(di-n-propylamino)tetralin - pharmacology</topic><topic>Animals</topic><topic>Aniracetam</topic><topic>Anti-Anxiety Agents - pharmacology</topic><topic>Anxiety</topic><topic>Anxiety - physiopathology</topic><topic>Anxiety - prevention & control</topic><topic>Anxiety - psychology</topic><topic>Behavior, Animal - drug effects</topic><topic>Biological and medical sciences</topic><topic>Bromocriptine - pharmacology</topic><topic>Conditioned fear stress</topic><topic>Diazepam - pharmacology</topic><topic>Disease Models, Animal</topic><topic>Dopamine Antagonists - pharmacology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Elevated plus-maze</topic><topic>Fear - psychology</topic><topic>Fluvoxamine - pharmacology</topic><topic>Haloperidol - pharmacology</topic><topic>Indophenol - analogs & derivatives</topic><topic>Indophenol - pharmacology</topic><topic>Male</topic><topic>Maze Learning - drug effects</topic><topic>Mecamylamine - pharmacology</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred ICR</topic><topic>Moclobemide - pharmacology</topic><topic>Mode of action</topic><topic>Motor Activity - drug effects</topic><topic>Neuropharmacology</topic><topic>Nicotine - pharmacology</topic><topic>Nicotinic Antagonists - pharmacology</topic><topic>Nortriptyline - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Physostigmine - pharmacology</topic><topic>Picolinic Acids - pharmacology</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Pyrrolidinones - pharmacology</topic><topic>Serotonin Antagonists - pharmacology</topic><topic>Serotonin Receptor Agonists - pharmacology</topic><topic>Social Behavior</topic><topic>Social interaction</topic><topic>Stress, Psychological - physiopathology</topic><topic>Stress, Psychological - prevention & control</topic><topic>Stress, Psychological - psychology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakamura, Kazuo</creatorcontrib><creatorcontrib>Kurasawa, Mitsue</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakamura, Kazuo</au><au>Kurasawa, Mitsue</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2001-05-18</date><risdate>2001</risdate><volume>420</volume><issue>1</issue><spage>33</spage><epage>43</epage><pages>33-43</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>The anxiolytic effects of aniracetam have not been proven in animals despite its clinical usefulness for post-stroke anxiety. This study, therefore, aimed to characterize the anxiolytic effects of aniracetam in different anxiety models using mice and to examine the mode of action. In a social interaction test in which all classes (serotonergic, cholinergic and dopaminergic) of compounds were effective, aniracetam (10–100 mg/kg) increased total social interaction scores (time and frequency), and the increase in the total social interaction time mainly reflected an increase in trunk sniffing and following. The anxiolytic effects were completely blocked by haloperidol and nearly completely by mecamylamine or ketanserin, suggesting an involvement of nicotinic acetylcholine, 5-HT
2A and dopamine D
2 receptors in the anxiolytic mechanism. Aniracetam also showed anti-anxiety effects in two other anxiety models (elevated plus-maze and conditioned fear stress tests), whereas diazepam as a positive control was anxiolytic only in the elevated plus-maze and social interaction tests. The anxiolytic effects of aniracetam in each model were mimicked by different metabolites (i.e.,
p-anisic acid in the elevated plus-maze test) or specific combinations of metabolites. These results indicate that aniracetam possesses a wide range of anxiolytic properties, which may be mediated by an interaction between cholinergic, dopaminergic and serotonergic systems. Thus, our findings suggest the potential usefulness of aniracetam against various types of anxiety-related disorders and social failure/impairments.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>11412837</pmid><doi>10.1016/S0014-2999(01)01005-6</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-2999 |
| ispartof | European journal of pharmacology, 2001-05, Vol.420 (1), p.33-43 |
| issn | 0014-2999 1879-0712 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70942342 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | 8-Hydroxy-2-(di-n-propylamino)tetralin - pharmacology Animals Aniracetam Anti-Anxiety Agents - pharmacology Anxiety Anxiety - physiopathology Anxiety - prevention & control Anxiety - psychology Behavior, Animal - drug effects Biological and medical sciences Bromocriptine - pharmacology Conditioned fear stress Diazepam - pharmacology Disease Models, Animal Dopamine Antagonists - pharmacology Dose-Response Relationship, Drug Elevated plus-maze Fear - psychology Fluvoxamine - pharmacology Haloperidol - pharmacology Indophenol - analogs & derivatives Indophenol - pharmacology Male Maze Learning - drug effects Mecamylamine - pharmacology Medical sciences Mice Mice, Inbred ICR Moclobemide - pharmacology Mode of action Motor Activity - drug effects Neuropharmacology Nicotine - pharmacology Nicotinic Antagonists - pharmacology Nortriptyline - pharmacology Pharmacology. Drug treatments Physostigmine - pharmacology Picolinic Acids - pharmacology Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Pyrrolidinones - pharmacology Serotonin Antagonists - pharmacology Serotonin Receptor Agonists - pharmacology Social Behavior Social interaction Stress, Psychological - physiopathology Stress, Psychological - prevention & control Stress, Psychological - psychology |
| title | Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T21%3A07%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anxiolytic%20effects%20of%20aniracetam%20in%20three%20different%20mouse%20models%20of%20anxiety%20and%20the%20underlying%20mechanism&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Nakamura,%20Kazuo&rft.date=2001-05-18&rft.volume=420&rft.issue=1&rft.spage=33&rft.epage=43&rft.pages=33-43&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/S0014-2999(01)01005-6&rft_dat=%3Cproquest_cross%3E70942342%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70942342&rft_id=info:pmid/11412837&rft_els_id=S0014299901010056&rfr_iscdi=true |